Toxic neuropathies
- PMID: 37639472
- DOI: 10.1097/WCO.0000000000001193
Toxic neuropathies
Abstract
Purpose of review: Immunotherapy has had a significant impact on the treatment of an increasing number of cancers as well as in inflammatory, rheumatological and gastroenterological conditions.Recreational nitrous oxide use is now a global epidemic. Linezolid is now recommended for the treatment of drug-resistant tuberculosis (TB); neuropathy is a significant cause of morbidity.Global warming will result in increasing toxin exposure, such as ciguatera, in previously unaffected areas.
Recent findings: With increasing experience, the pathophysiology underlying the neuropathic complications of these drugs has become clear with guidelines now available, for the complications of immune check-point inhibitors and nitrous oxide toxicity. The optimum dose and duration of treatment for resistant TB with regimens, including linezolid, has been ascertained.
Summary: Although neuropathic complications with immunotherapy are relatively rare, it is essential that they are recognized and treated early. Nitrous oxide toxicity should be in the differential diagnosis for all patients, particularly those of younger age, presenting with a neuropathy or myleo-neuropathy. Ciguatera toxicity is under recognized and its geographical spread will increase due to global warming. Further research is necessary on the mechanisms and treatment of both acute and chronic effects, which at present, are only symptomatic.
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
References
-
- Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965; 58:295–300.
-
- Shimonovich M, Pearce A, Thomson H, et al. Assessing causality in epidemiology: revisiting Bradford Hill to incorporate developments in causal thinking. Eur J Epidemiol 2021; 36:873–887.
-
- Bruna J, Argyriou AA, Anastopoulou GG, et al. Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: experience beyond the clinical trials. J Peripher Nerv Syst 2020; 25:171–177.
-
- Dubey D, David WS, Amato AA, et al. Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology 2019; 93:e1093–e1103.
-
- Khan E, Shrestha AK, Elkhooly M, et al. CNS and PNS manifestation in immune checkpoint inhibitors: a systematic review. J Neurol Sci 2022; 432:120089.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials